{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:58:12Z","timestamp":1787003892586,"version":"build-2736575974"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T00:00:00Z","timestamp":1729728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T00:00:00Z","timestamp":1729728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Praxis Spinal Cord Injury Foundation ICORD student exchange grant"},{"DOI":"10.13039\/100001810","name":"Paralyzed Veterans of America Research Foundation","doi-asserted-by":"publisher","award":["3195"],"award-info":[{"award-number":["3195"]}],"id":[{"id":"10.13039\/100001810","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008191","name":"Wings for Life","doi-asserted-by":"publisher","award":["2017_044"],"award-info":[{"award-number":["2017_044"]}],"id":[{"id":"10.13039\/100008191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008191","name":"Wings for Life","doi-asserted-by":"publisher","award":["2020_118"],"award-info":[{"award-number":["2020_118"]}],"id":[{"id":"10.13039\/100008191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["PZ00P3_186101"],"award-info":[{"award-number":["PZ00P3_186101"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["IZLIZ3_200275"],"award-info":[{"award-number":["IZLIZ3_200275"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001708","name":"International Foundation for Research in Paraplegia","doi-asserted-by":"publisher","award":["P192"],"award-info":[{"award-number":["P192"]}],"id":[{"id":"10.13039\/501100001708","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Complications arising from acute traumatic spinal cord injury\u00a0(SCI) are routinely managed by various pharmacological interventions. Despite decades of clinical application, the potential impact on neurological recovery has been largely overlooked. This study aims to highlight commonly administered drugs with potential disease-modifying effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This systematic literature review included studies referenced in PubMed, Scopus and Web of Science from inception to March 31st, 2021, which assess disease-modifying properties on neurological and\/or functional recovery of drugs routinely administered following spinal cord injury. Drug effects were classified as positive, negative, mixed, no effect, or not (statistically) reported. Risk of bias was assessed separately for animal, randomized clinical trials, and observational human studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We analyzed 394 studies conducting 486 experiments that evaluated 144 unique or combinations of drugs. 195 of the 464 experiments conducted on animals (42%) and one study in humans demonstrate positive disease-modifying properties on neurological and\/or functional outcomes. Methylprednisolone, melatonin, estradiol, and atorvastatin are the most common drugs associated with positive effects. Two studies on morphine and ethanol report negative effects on recovery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Despite a large heterogeneity observed in study protocols, research from bed to bench and back to bedside provides an alternative approach to identify new candidate drugs in the context of SCI. Future research in human populations is warranted to determine if introducing drugs like melatonin, estradiol, or atorvastatin would contribute to enhancing neurological outcomes after acute SCI.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s43856-024-00638-0","type":"journal-article","created":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T06:02:44Z","timestamp":1729749764000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Impact of commonly administered drugs on the progression of spinal cord injury: a systematic review"],"prefix":"10.1038","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8049-6461","authenticated-orcid":false,"given":"Lucie","family":"Bourguignon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9307-0945","authenticated-orcid":false,"given":"Louis P.","family":"Lukas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9297-8529","authenticated-orcid":false,"given":"Bethany R.","family":"Kondiles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bobo","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6246-2773","authenticated-orcid":false,"given":"Jaimie J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1s","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfram","family":"Tetzlaff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L. K.","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5347-1584","authenticated-orcid":false,"given":"Matthias","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine R.","family":"Jutzeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,24]]},"reference":[{"key":"638_CR1","doi-asserted-by":"publisher","unstructured":"Tian, T., Zhang, S. & Yang, M. Recent progress and challenges in the treatment of spinal cord injury. Protein Cell. https:\/\/doi.org\/10.1093\/procel\/pwad003 (2023).","DOI":"10.1093\/procel\/pwad003"},{"key":"638_CR2","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1007\/s13311-018-0632-5","volume":"15","author":"J Donovan","year":"2018","unstructured":"Donovan, J. & Kirshblum, S. Clinical trials in traumatic spinal cord injury. Neurotherapeutics 15, 654\u2013668 (2018).","journal-title":"Neurotherapeutics"},{"key":"638_CR3","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s40263-019-00622-6","volume":"33","author":"FM Warner","year":"2019","unstructured":"Warner, F. M. et al. The effect of non-gabapentinoid anticonvulsants on sensorimotor recovery after human spinal cord injury. CNS Drugs 33, 503\u2013511 (2019).","journal-title":"CNS Drugs"},{"key":"638_CR4","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1007\/s13311-019-00713-8","volume":"16","author":"JJ Cragg","year":"2019","unstructured":"Cragg, J. J. et al. A longitudinal study of the neurologic safety of acute baclofen use after spinal cord injury. Neurotherapeutics 16, 858\u2013867 (2019).","journal-title":"Neurotherapeutics"},{"key":"638_CR5","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1177\/1545968315624777","volume":"30","author":"JJ Cragg","year":"2016","unstructured":"Cragg, J. J. et al. Effects of pain and pain management on motor recovery of spinal cord-injured patients: a longitudinal study. Neurorehabil. Neural Repair 30, 753\u2013761 (2016).","journal-title":"Neurorehabil. Neural Repair"},{"key":"638_CR6","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1016\/j.celrep.2017.01.048","volume":"18","author":"FM Warner","year":"2017","unstructured":"Warner, F. M. et al. Early administration of gabapentinoids improves motor recovery after human spinal cord injury. Cell Rep. 18, 1614\u20131618 (2017).","journal-title":"Cell Rep."},{"key":"638_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-31773-8","volume":"13","author":"CR Jutzeler","year":"2023","unstructured":"Jutzeler, C. R. et al. Pharmacological management of acute spinal cord injury: a longitudinal multi-cohort observational study. Sci. Rep. 13, 5434 (2023).","journal-title":"Sci. Rep."},{"key":"638_CR8","doi-asserted-by":"publisher","first-page":"3858","DOI":"10.1080\/09638288.2019.1610085","volume":"42","author":"L Cadel","year":"2020","unstructured":"Cadel, L. et al. Spinal cord injury and polypharmacy: a scoping review. Disabil. Rehabil. 42, 3858\u20133870 (2020).","journal-title":"Disabil. Rehabil."},{"key":"638_CR9","doi-asserted-by":"crossref","unstructured":"Paker, N., Soluk \u00d6zdemir, Y., Bu\u011fdayc\u0131, D., \u00c7elik, B. & B\u00f6l\u00fckba\u015f Y. Prevalence and predictors of polypharmacy among community-based individuals with traumatic spinal cord injury. J. Spinal Cord Med. 46, 958\u2013963 (2023).","DOI":"10.1080\/10790268.2021.2008700"},{"key":"638_CR10","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1007\/s12035-016-9895-1","volume":"54","author":"D Zhang","year":"2017","unstructured":"Zhang, D. et al. Metformin improves functional recovery after spinal cord injury via autophagy flux stimulation. Mol. Neurobiol. 54, 3327\u20133341 (2017).","journal-title":"Mol. Neurobiol."},{"key":"638_CR11","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1177\/2192568220901689","volume":"11","author":"MJ Lambrechts","year":"2021","unstructured":"Lambrechts, M. J. & Cook, J. L. Nonsteroidal anti-inflammatory drugs and their neuroprotective role after an acute spinal cord injury: a systematic review of animal models. Glob. Spine J. 11, 365\u2013377 (2021).","journal-title":"Glob. Spine J."},{"key":"638_CR12","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1089\/neu.2007.0464","volume":"26","author":"X Wang","year":"2009","unstructured":"Wang, X. et al. Ibuprofen enhances recovery from spinal cord injury by limiting tissue loss and stimulating axonal growth. J. Neurotrauma 26, 81\u201395 (2009).","journal-title":"J. Neurotrauma"},{"key":"638_CR13","volume":"2020","author":"H Wang","year":"2020","unstructured":"Wang, H. et al. Metformin promotes axon regeneration after spinal cord injury through inhibiting oxidative stress and stabilizing microtubule. Oxid. Med. Cell Longev. 2020, 9741369 (2020).","journal-title":"Oxid. Med. Cell Longev."},{"key":"638_CR14","doi-asserted-by":"publisher","first-page":"704","DOI":"10.3171\/jns.1985.63.5.0704","volume":"63","author":"MB Bracken","year":"1985","unstructured":"Bracken, M. B. et al. Methylprednisolone and neurological function 1 year after spinal cord injury. Results of the National Acute Spinal Cord Injury Study. J. Neurosurg. 63, 704\u2013713 (1985).","journal-title":"J. Neurosurg."},{"key":"638_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.wneu.2021.02.116","volume":"150","author":"JA Canseco","year":"2021","unstructured":"Canseco, J. A. et al. Updated review: the steroid controversy for management of spinal cord injury. World Neurosurg. 150, 1\u20138 (2021).","journal-title":"World Neurosurg."},{"key":"638_CR16","doi-asserted-by":"crossref","unstructured":"Shamseer, L. et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 349, g7647 (2015).","DOI":"10.1136\/bmj.g7647"},{"key":"638_CR17","doi-asserted-by":"publisher","first-page":"S87","DOI":"10.1097\/00007632-200112151-00015","volume":"26","author":"FH Geisler","year":"2001","unstructured":"Geisler, F. H., Coleman, W. P., Grieco, G. & Poonian, D. Sygen Study Group. The Sygen multicenter acute spinal cord injury study. Spine 26, S87\u2013S98 (2001).","journal-title":"Spine"},{"key":"638_CR18","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1080\/10790268.2009.11760779","volume":"32","author":"G Whiteneck","year":"2009","unstructured":"Whiteneck, G., Gassaway, J., Dijkers, M. & Jha, A. New approach to study the contents and outcomes of spinal cord injury rehabilitation: the SCIRehab Project. J. Spinal Cord. Med. 32, 251\u2013259 (2009).","journal-title":"J. Spinal Cord. Med."},{"key":"638_CR19","unstructured":"Harzing, A. -W. Publish or Perish. Available from https:\/\/harzing.com\/resources\/publish-or-perish (2007)."},{"key":"638_CR20","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne, J. A. C. et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366, l4898 (2019).","journal-title":"BMJ"},{"key":"638_CR21","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne, J. A. et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355, i4919 (2016).","journal-title":"BMJ"},{"key":"638_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-43","volume":"14","author":"CR Hooijmans","year":"2014","unstructured":"Hooijmans, C. R. et al. SYRCLE\u2019s risk of bias tool for animal studies. BMC Med. Res. Methodol. 14, 43 (2014).","journal-title":"BMC Med. Res. Methodol."},{"key":"638_CR23","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","volume":"12","author":"LA McGuinness","year":"2021","unstructured":"McGuinness, L. A. & Higgins, J. P. T. Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res. Synth. Methods 12, 55\u201361 (2021).","journal-title":"Res. Synth. Methods"},{"key":"638_CR24","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/0736-5748(91)90002-4","volume":"9","author":"NE Naftchi","year":"1991","unstructured":"Naftchi, N. E. Treatment of mammalian spinal cord injury with antioxidants. Int. J. Dev. Neurosci. 9, 113\u2013126 (1991).","journal-title":"Int. J. Dev. Neurosci."},{"key":"638_CR25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ejphar.2014.07.042","volume":"741","author":"R Kahveci","year":"2014","unstructured":"Kahveci, R. et al. Neuroprotective effects of rosuvastatin against traumatic spinal cord injury in rats. Eur. J. Pharm. 741, 45\u201354 (2014).","journal-title":"Eur. J. Pharm."},{"key":"638_CR26","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1089\/neu.2009.0884","volume":"26","author":"BK Kwon","year":"2009","unstructured":"Kwon, B. K. et al. Magnesium chloride in a polyethylene glycol formulation as a neuroprotective therapy for acute spinal cord injury: preclinical refinement and optimization. J. Neurotrauma 26, 1379\u20131393 (2009).","journal-title":"J. Neurotrauma"},{"key":"638_CR27","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1089\/neu.2016.4439","volume":"33","author":"F Streijger","year":"2016","unstructured":"Streijger, F. et al. The evaluation of magnesium chloride within a polyethylene glycol formulation in a porcine model of acute spinal cord injury. J. Neurotrauma 33, 2202\u20132216 (2016).","journal-title":"J. Neurotrauma"},{"key":"638_CR28","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1001\/archneur.1992.00530350096025","volume":"49","author":"PS Halt","year":"1992","unstructured":"Halt, P. S., Swanson, R. A. & Faden, A. I. Alcohol exacerbates behavioral and neurochemical effects of rat spinal cord trauma. Arch. Neurol. 49, 1178\u20131184 (1992).","journal-title":"Arch. Neurol."},{"key":"638_CR29","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3171\/jns.1979.50.3.0349","volume":"50","author":"AS Rivlin","year":"1979","unstructured":"Rivlin, A. S. & Tator, C. H. Effect of vasodilators and myelotomy on recovery after acute spinal cord injury in rats. J. Neurosurg. 50, 349\u2013352 (1979).","journal-title":"J. Neurosurg."},{"key":"638_CR30","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/sc.2014.91","volume":"52","author":"T Cheriyan","year":"2014","unstructured":"Cheriyan, T. et al. Spinal cord injury models: a review. Spinal Cord. 52, 588\u2013595 (2014).","journal-title":"Spinal Cord."},{"key":"638_CR31","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/BF03018241","volume":"51","author":"S Lopez","year":"2004","unstructured":"Lopez, S. et al. Intrathecal bupivacaine protects against extension of lesions in an acute photochemical spinal cord injury model. Can. J. Anaesth. 51, 364\u2013372 (2004).","journal-title":"Can. J. Anaesth."},{"key":"638_CR32","first-page":"257","volume":"3","author":"JX Hao","year":"1991","unstructured":"Hao, J. X., Xu, X. J., Aldskogius, H., Seiger, A. & Wiesenfeld-Hallin, Z. Beneficial effect of the opioid receptor antagonist naltrexone on hyper-sensitivity induced by spinal cord ischemia in rats: disassociation with MK-801. Restor. Neurol. Neurosci. 3, 257\u2013266 (1991).","journal-title":"Restor. Neurol. Neurosci."},{"key":"638_CR33","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1006\/exnr.1998.6974","volume":"154","author":"JR Madsen","year":"1998","unstructured":"Madsen, J. R. et al. Tacrolimus (FK506) increases neuronal expression of GAP-43 and improves functional recovery after spinal cord injury in rats. Exp. Neurol. 154, 673\u2013683 (1998).","journal-title":"Exp. Neurol."},{"key":"638_CR34","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1007\/s00701-014-2119-4","volume":"156","author":"M-S Piao","year":"2014","unstructured":"Piao, M.-S. et al. Melatonin improves functional outcome via inhibition of matrix metalloproteinases-9 after photothrombotic spinal cord injury in rats. Acta Neurochir. 156, 2173\u20132182 (2014).","journal-title":"Acta Neurochir."},{"key":"638_CR35","first-page":"157","volume":"20","author":"M Afhami","year":"2016","unstructured":"Afhami, M. et al. The demyelination and altered motor performance following electrolytic lesion in the ventrolateral white matter of spinal cord in male rats: benefit of post-injury administration of estradiol. Life Sci. I 20, 157\u2013171 (2016).","journal-title":"Life Sci. I"},{"key":"638_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/neu.1995.12.1","volume":"12","author":"DM Basso","year":"1995","unstructured":"Basso, D. M., Beattie, M. S. & Bresnahan, J. C. A sensitive and reliable locomotor rating scale for open field testing in rats. J. Neurotrauma 12, 1\u201321 (1995).","journal-title":"J. Neurotrauma"},{"key":"638_CR37","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1089\/neu.2006.23.635","volume":"23","author":"DM Basso","year":"2006","unstructured":"Basso, D. M. et al. Basso Mouse Scale for locomotion detects differences in recovery after spinal cord injury in five common mouse strains. J. Neurotrauma 23, 635\u2013659 (2006).","journal-title":"J. Neurotrauma"},{"key":"638_CR38","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jneumeth.2016.04.023","volume":"268","author":"RB Song","year":"2016","unstructured":"Song, R. B. et al. Adaptation of the Basso-Beattie-Bresnahan locomotor rating scale for use in a clinical model of spinal cord injury in dogs. J. Neurosci. Methods 268, 117\u2013124 (2016).","journal-title":"J. Neurosci. Methods"},{"key":"638_CR39","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1089\/neu.2016.4507","volume":"34","author":"MA Hook","year":"2017","unstructured":"Hook, M. A. et al. Neurobiological effects of morphine after spinal cord injury. J. Neurotrauma 34, 632\u2013644 (2017).","journal-title":"J. Neurotrauma"},{"key":"638_CR40","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1089\/neu.2013.3206","volume":"31","author":"KA Leech","year":"2014","unstructured":"Leech, K. A., Kinnaird, C. R. & Hornby, T. G. Effects of serotonergic medications on locomotor performance in humans with incomplete spinal cord injury. J. Neurotrauma 31, 1334\u20131342 (2014).","journal-title":"J. Neurotrauma"},{"key":"638_CR41","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1089\/neu.2015.3963","volume":"32","author":"N Evaniew","year":"2015","unstructured":"Evaniew, N. et al. Methylprednisolone for the treatment of patients with acute spinal cord injuries: a propensity score-matched cohort study from a Canadian multi-center spinal cord injury registry. J. Neurotrauma 32, 1674\u20131683 (2015).","journal-title":"J. Neurotrauma"},{"key":"638_CR42","doi-asserted-by":"publisher","first-page":"7","DOI":"10.5535\/arm.20148","volume":"45","author":"HS Kim","year":"2021","unstructured":"Kim, H. S. et al. Epidemiology of spinal cord injury: changes to its cause amid aging population, a single center study. Ann. Rehabil. Med. 45, 7\u201315 (2021).","journal-title":"Ann. Rehabil. Med."},{"key":"638_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/JN.S143236","volume":"6","author":"Y Kang","year":"2017","unstructured":"Kang, Y. et al. Epidemiology of worldwide spinal cord injury: a literature review. J. Neurorestoratol. 6, 1\u20139 (2017).","journal-title":"J. Neurorestoratol."},{"key":"638_CR44","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/sc.2011.178","volume":"50","author":"MJ Devivo","year":"2012","unstructured":"Devivo, M. J. Epidemiology of traumatic spinal cord injury: trends and future implications. Spinal Cord. 50, 365\u2013372 (2012).","journal-title":"Spinal Cord."},{"key":"638_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02395-0","volume":"20","author":"L Bourguignon","year":"2022","unstructured":"Bourguignon, L. et al. International surveillance study in acute spinal cord injury confirms viability of multinational clinical trials. BMC Med. 20, 225 (2022).","journal-title":"BMC Med."},{"key":"638_CR46","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1056\/NEJM199005173222001","volume":"322","author":"MB Bracken","year":"1990","unstructured":"Bracken, M. B. et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N. Engl. J. Med. 322, 1405\u20131411 (1990).","journal-title":"N. Engl. J. Med."},{"key":"638_CR47","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1097\/BRS.0b013e3181b613c7","volume":"34","author":"Y Ito","year":"2009","unstructured":"Ito, Y., Sugimoto, Y., Tomioka, M., Kai, N. & Tanaka, M. Does high dose methylprednisolone sodium succinate really improve neurological status in patient with acute cervical cord injury?: a prospective study about neurological recovery and early complications. Spine 34, 2121\u20132124 (2009).","journal-title":"Spine"},{"key":"638_CR48","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1179\/2045772312Y.0000000021","volume":"35","author":"G-Z Ning","year":"2012","unstructured":"Ning, G.-Z., Wu, Q., Li, Y.-L. & Feng, S.-Q. Epidemiology of traumatic spinal cord injury in Asia: a systematic review. J. Spinal Cord. Med 35, 229\u2013239 (2012).","journal-title":"J. Spinal Cord. Med"},{"key":"638_CR49","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000350710","volume":"41","author":"V Rahimi-Movaghar","year":"2013","unstructured":"Rahimi-Movaghar, V. et al. Epidemiology of traumatic spinal cord injury in developing countries: a systematic review. Neuroepidemiology 41, 65\u201385 (2013).","journal-title":"Neuroepidemiology"},{"key":"638_CR50","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1089\/neu.2012.2515","volume":"30","author":"CK Thompson","year":"2013","unstructured":"Thompson, C. K. & Hornby, T. G. Divergent modulation of clinical measures of volitional and reflexive motor behaviors following serotonergic medications in human incomplete spinal cord injury. J. Neurotrauma 30, 498\u2013502 (2013).","journal-title":"J. Neurotrauma"},{"key":"638_CR51","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1089\/neu.2008.0583","volume":"25","author":"O Maric","year":"2008","unstructured":"Maric, O., Z\u00f6rner, B. & Dietz, V. Levodopa therapy in incomplete spinal cord injury. J. Neurotrauma 25, 1303\u20131307 (2008).","journal-title":"J. Neurotrauma"},{"key":"638_CR52","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3171\/jns.1992.76.1.0023","volume":"76","author":"MB Bracken","year":"1992","unstructured":"Bracken, M. B. et al. Methylprednisolone or naloxone treatment after acute spinal cord injury: 1-year follow-up data: results of the second National Acute Spinal Cord Injury Study. J. Neurosurg. 76, 23\u201331 (1992).","journal-title":"J. Neurosurg."},{"key":"638_CR53","doi-asserted-by":"publisher","first-page":"500","DOI":"10.3171\/jns.1993.79.4.0500","volume":"79","author":"MB Bracken","year":"1993","unstructured":"Bracken, M. B. & Holford, T. R. Effects of timing of methylprednisolone or naloxone administration on recovery of segmental and long-tract neurological function in NASCIS 2. J. Neurosurg. 79, 500\u2013507 (1993).","journal-title":"J. Neurosurg."},{"key":"638_CR54","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1093\/brain\/aws072","volume":"135","author":"S Casha","year":"2012","unstructured":"Casha, S. et al. Results of a phase II placebo-controlled randomized trial of minocycline in acute spinal cord injury. Brain 135, 1224\u20131236 (2012).","journal-title":"Brain"},{"key":"638_CR55","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/PHM.0b013e318168bbec","volume":"87","author":"MJ Clark","year":"2008","unstructured":"Clark, M. J. et al. Testosterone replacement therapy and motor function in men with spinal cord injury: a retrospective analysis. Am. J. Phys. Med. Rehabil. 87, 281\u2013284 (2008).","journal-title":"Am. J. Phys. Med. Rehabil."},{"key":"638_CR56","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1080\/10790268.2015.1114224","volume":"39","author":"B Aminmansour","year":"2016","unstructured":"Aminmansour, B. et al. Effects of progesterone and vitamin D on outcome of patients with acute traumatic spinal cord injury; a randomized, double-blind, placebo controlled study. J. Spinal Cord. Med. 39, 272\u2013280 (2016).","journal-title":"J. Spinal Cord. Med."},{"key":"638_CR57","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1089\/neu.2017.5535","volume":"35","author":"JR Wilson","year":"2018","unstructured":"Wilson, J. R. et al. Natural history, predictors of outcome, and effects of treatment in thoracic spinal cord injury: a multi-center cohort study from the North American Clinical Trials Network. J. Neurotrauma 35, 2554\u20132560 (2018).","journal-title":"J. Neurotrauma"},{"key":"638_CR58","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1213\/ANE.0000000000001906","volume":"124","author":"JE Sunshine","year":"2017","unstructured":"Sunshine, J. E. et al. Methylprednisolone therapy in acute traumatic spinal cord injury: analysis of a regional spinal cord model systems database. Anesth. Analg. 124, 1200\u20131205 (2017).","journal-title":"Anesth. Analg."},{"key":"638_CR59","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1097\/BRS.0b013e31823a07a2","volume":"37","author":"P Felleiter","year":"2012","unstructured":"Felleiter, P., M\u00fcller, N., Schumann, F., Felix, O. & Lierz, P. Changes in the use of the methylprednisolone protocol for traumatic spinal cord injury in Switzerland. Spine 37, 953\u2013956 (2012).","journal-title":"Spine"},{"key":"638_CR60","doi-asserted-by":"crossref","unstructured":"Tsutsumi, S., Ueta, T., Shiba, K., Yamamoto, S. & Takagishi, K. Effects of the second national acute spinal cord injury study of high-dose methylprednisolone therapy on acute cervical spinal cord injury-results in spinal injuries center. Spine 31, 2992\u20132996 (2006).","DOI":"10.1097\/01.brs.0000250273.28483.5c"},{"key":"638_CR61","first-page":"337","volume":"24","author":"OA Nacar","year":"2014","unstructured":"Nacar, O. A. et al. Systemic administration of atorvastatin improves locomotor functions and hyperacute-acute response after experimental spinal cord injury: an ultrastructural and biochemical analysis. Turk. Neurosurg. 24, 337\u2013343 (2014).","journal-title":"Turk. Neurosurg."},{"key":"638_CR62","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.4103\/1673-5374.241473","volume":"13","author":"D Zhang","year":"2018","unstructured":"Zhang, D., Wang, F., Zhai, X., Li, X.-H. & He, X.-J. Lithium promotes recovery of neurological function after spinal cord injury by inducing autophagy. Neural Regen. Res 13, 2191\u20132199 (2018).","journal-title":"Neural Regen. Res"},{"key":"638_CR63","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1007\/s12264-013-1355-6","volume":"29","author":"H-H Hao","year":"2013","unstructured":"Hao, H.-H. et al. Valproic acid reduces autophagy and promotes functional recovery after spinal cord injury in rats. Neurosci. Bull. 29, 484\u2013492 (2013).","journal-title":"Neurosci. Bull."},{"key":"638_CR64","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1002\/jnr.24409","volume":"97","author":"Y Zhang","year":"2019","unstructured":"Zhang, Y. et al. Melatonin improves functional recovery in female rats after acute spinal cord injury by modulating polarization of spinal microglial\/macrophages. J. Neurosci. Res. 97, 733\u2013743 (2019).","journal-title":"J. Neurosci. Res."},{"key":"638_CR65","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1212\/WNL.0b013e31824e8f0d","volume":"78","author":"G Hubsher","year":"2012","unstructured":"Hubsher, G., Haider, M. & Okun, M. S. Amantadine: the journey from fighting flu to treating Parkinson disease. Neurology 78, 1096\u20131099 (2012).","journal-title":"Neurology"},{"key":"638_CR66","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/nrd3869","volume":"11","author":"A Corbett","year":"2012","unstructured":"Corbett, A. et al. Drug repositioning for Alzheimer\u2019s disease. Nat. Rev. Drug Discov. 11, 833\u2013846 (2012).","journal-title":"Nat. Rev. Drug Discov."},{"key":"638_CR67","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd1468","volume":"3","author":"TT Ashburn","year":"2004","unstructured":"Ashburn, T. T. & Thor, K. B. Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 3, 673\u2013683 (2004).","journal-title":"Nat. Rev. Drug Discov."},{"key":"638_CR68","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/534314a","volume":"534","author":"N Nosengo","year":"2016","unstructured":"Nosengo, N. Can you teach old drugs new tricks? Nature 534, 314\u2013316 (2016).","journal-title":"Nature"},{"key":"638_CR69","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.expneurol.2013.05.012","volume":"248","author":"BK Kwon","year":"2013","unstructured":"Kwon, B. K. et al. Demonstrating efficacy in preclinical studies of cellular therapies for spinal cord injury - how much is enough? Exp. Neurol. 248, 30\u201344 (2013).","journal-title":"Exp. Neurol."},{"key":"638_CR70","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1758-5996-5-6","volume":"5","author":"LBA Rojas","year":"2013","unstructured":"Rojas, L. B. A. & Gomes, M. B. Metformin: an old but still the best treatment for type 2 diabetes. Diabetol. Metab. Syndr. 5, 6 (2013).","journal-title":"Diabetol. Metab. Syndr."},{"key":"638_CR71","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s11064-018-2525-8","volume":"43","author":"Y Guo","year":"2018","unstructured":"Guo, Y. et al. Metformin protects against spinal cord injury by regulating autophagy via the mTOR signaling pathway. Neurochem. Res. 43, 1111\u20131117 (2018).","journal-title":"Neurochem. Res."},{"key":"638_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2020.135440","volume":"739","author":"T Zhang","year":"2020","unstructured":"Zhang, T. et al. Therapeutic effect of metformin on inflammation and apoptosis after spinal cord injury in rats through the Wnt\/\u03b2-catenin signaling pathway. Neurosci. Lett. 739, 135440 (2020).","journal-title":"Neurosci. Lett."},{"key":"638_CR73","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.bbr.2007.02.035","volume":"179","author":"MA Hook","year":"2007","unstructured":"Hook, M. A. et al. The impact of morphine after a spinal cord injury. Behav. Brain Res 179, 281\u2013293 (2007).","journal-title":"Behav. Brain Res"},{"key":"638_CR74","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1089\/neu.2008.0710","volume":"26","author":"MA Hook","year":"2009","unstructured":"Hook, M. A. et al. Intrathecal morphine attenuates recovery of function after a spinal cord injury. J. Neurotrauma 26, 741\u2013752 (2009).","journal-title":"J. Neurotrauma"},{"key":"638_CR75","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.bbi.2010.10.018","volume":"25","author":"MA Hook","year":"2011","unstructured":"Hook, M. A. et al. An IL-1 receptor antagonist blocks a morphine-induced attenuation of locomotor recovery after spinal cord injury. Brain Behav. Immun. 25, 349\u2013359 (2011).","journal-title":"Brain Behav. Immun."},{"key":"638_CR76","doi-asserted-by":"crossref","unstructured":"Woller, S. A. Analgesia Or Addiction: Implications for Morphine Use After Spinal Cord Injury (Texas A & M University, 2012).","DOI":"10.1089\/neu.2011.2100"},{"key":"638_CR77","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1126\/science.7455690","volume":"211","author":"AI Faden","year":"1981","unstructured":"Faden, A. I., Jacobs, T. P. & Holaday, J. W. Opiate antagonist improves neurologic recovery after spinal injury. Science 211, 493\u2013494 (1981).","journal-title":"Science"},{"key":"638_CR78","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1212\/WNL.32.6.677","volume":"32","author":"AI Faden","year":"1982","unstructured":"Faden, A. I., Jacobs, T. P. & Holaday, J. W. Comparison of early and late naloxone treatment in experimental spinal injury. Neurology 32, 677\u2013681 (1982).","journal-title":"Neurology"},{"key":"638_CR79","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.expneurol.2010.11.016","volume":"233","author":"PG Popovich","year":"2012","unstructured":"Popovich, P. G., Lemeshow, S., Gensel, J. C. & Tovar, C. A. Independent evaluation of the effects of glibenclamide on reducing progressive hemorrhagic necrosis after cervical spinal cord injury. Exp. Neurol. 233, 615\u2013622 (2012).","journal-title":"Exp. Neurol."},{"key":"638_CR80","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1590\/S0102-67202012000100011","volume":"25","author":"NA Andreollo","year":"2012","unstructured":"Andreollo, N. A., Santos, E. F., dos Ara\u00fajo, M. R. & Lopes, L. R. Rat\u2019s age versus human\u2019s age: what is the relationship? Arq. Bras. Cir. Dig. 25, 49\u201351 (2012).","journal-title":"Arq. Bras. Cir. Dig."},{"key":"638_CR81","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.lfs.2015.10.025","volume":"152","author":"S Dutta","year":"2016","unstructured":"Dutta, S. & Sengupta, P. Men and mice: Relating their ages. Life Sci. 152, 244\u2013248 (2016).","journal-title":"Life Sci."},{"key":"638_CR82","doi-asserted-by":"publisher","unstructured":"Cambridge, R. Modeling the age difference between humans and Felis catus biological cat age: the actual age of a cat. J. Anim. Res. Nutr. 02, https:\/\/doi.org\/10.21767\/2572-5459.100034 (2017).","DOI":"10.21767\/2572-5459.100034"},{"key":"638_CR83","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.cels.2020.06.006","volume":"11","author":"T Wang","year":"2020","unstructured":"Wang, T. et al. Quantitative translation of dog-to-human aging by conserved remodeling of the DNA methylome. Cell Syst. 11, 176\u201385.e6 (2020).","journal-title":"Cell Syst."},{"key":"638_CR84","doi-asserted-by":"publisher","first-page":"194","DOI":"10.4103\/ijpvm.IJPVM_530_18","volume":"11","author":"P Sengupta","year":"2020","unstructured":"Sengupta, P. & Dutta, S. Mapping the age of laboratory rabbit strains to human. Int. J. Prev. Med. 11, 194 (2020).","journal-title":"Int. J. Prev. Med."},{"key":"638_CR85","doi-asserted-by":"crossref","unstructured":"Flurkey, K., Mcurrer, J. & Harrison, D. Mouse models in aging research. in The Mouse in Biomedical Research 637\u2013672 (Elsevier, 2007).","DOI":"10.1016\/B978-012369454-6\/50074-1"},{"key":"638_CR86","doi-asserted-by":"publisher","unstructured":"Guest, J., Datta, N., Jimsheleishvili, G. & Gater, D. R. Jr. Pathophysiology, classification and comorbidities after traumatic spinal cord injury. J. Pers. Med. 12, https:\/\/doi.org\/10.3390\/jpm12071126 (2022).","DOI":"10.3390\/jpm12071126"},{"key":"638_CR87","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/sc.2010.116","volume":"49","author":"T Ueno","year":"2011","unstructured":"Ueno, T. et al. Hyperphosphorylated neurofilament NF-H as a biomarker of the efficacy of minocycline therapy for spinal cord injury. Spinal Cord. 49, 333\u2013336 (2011).","journal-title":"Spinal Cord."},{"key":"638_CR88","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1093\/brain\/aws171","volume":"135","author":"JY Lee","year":"2012","unstructured":"Lee, J. Y., Kim, H. S., Choi, H. Y., Oh, T. H. & Yune, T. Y. Fluoxetine inhibits matrix metalloprotease activation and prevents disruption of blood-spinal cord barrier after spinal cord injury. Brain 135, 2375\u20132389 (2012).","journal-title":"Brain"},{"key":"638_CR89","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.stemcr.2020.05.017","volume":"15","author":"P Assinck","year":"2020","unstructured":"Assinck, P. et al. Transplantation of skin precursor-derived schwann cells yields better locomotor outcomes and reduces bladder pathology in rats with chronic spinal cord injury. Stem Cell Rep. 15, 140\u2013155 (2020).","journal-title":"Stem Cell Rep."},{"key":"638_CR90","doi-asserted-by":"publisher","first-page":"4075","DOI":"10.1073\/pnas.1210293110","volume":"110","author":"BE Powers","year":"2013","unstructured":"Powers, B. E. et al. Remyelination reporter reveals prolonged refinement of spontaneously regenerated myelin. Proc. Natl. Acad. Sci. USA 110, 4075\u20134080 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"638_CR91","doi-asserted-by":"publisher","unstructured":"Ghnenis, A. B. et al. Evaluation of the cardiometabolic disorders after spinal cord injury in mice. Biology 11, https:\/\/doi.org\/10.3390\/biology11040495 (2022).","DOI":"10.3390\/biology11040495"},{"key":"638_CR92","doi-asserted-by":"publisher","unstructured":"Bourguignon, L., Lukas, L. P. & Jutzeler, C. Impact of commonly administered drugs on the progression of spinal cord injury: a systematic review (code and data). https:\/\/doi.org\/10.5281\/zenodo.13871856.","DOI":"10.5281\/zenodo.13871856"},{"key":"638_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2020.101517","volume":"34","author":"N Apostolova","year":"2020","unstructured":"Apostolova, N. et al. Mechanisms of action of metformin in type 2 diabetes: effects on mitochondria and leukocyte-endothelium interactions. Redox Biol. 34, 101517 (2020).","journal-title":"Redox Biol."},{"key":"638_CR94","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2022.946879","volume":"16","author":"L-Y Zhou","year":"2022","unstructured":"Zhou, L.-Y. et al. The effect of metformin on ameliorating neurological function deficits and tissue damage in rats following spinal cord injury: a systematic review and network meta-analysis. Front Neurosci. 16, 946879 (2022).","journal-title":"Front Neurosci."},{"key":"638_CR95","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/S0165-6147(02)02077-1","volume":"23","author":"G Weitz-Schmidt","year":"2002","unstructured":"Weitz-Schmidt, G. Statins as anti-inflammatory agents. Trends Pharm. Sci. 23, 482\u2013486 (2002).","journal-title":"Trends Pharm. Sci."},{"key":"638_CR96","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1089\/neu.2006.23.1366","volume":"23","author":"E Holmberg","year":"2006","unstructured":"Holmberg, E. et al. Simvastatin promotes neurite outgrowth in the presence of inhibitory molecules found in central nervous system injury. J. Neurotrauma 23, 1366\u20131378 (2006).","journal-title":"J. Neurotrauma"},{"key":"638_CR97","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.phrs.2014.06.007","volume":"88","author":"AM Malfitano","year":"2014","unstructured":"Malfitano, A. M. et al. Statins in neurological disorders: an overview and update. Pharm. Res 88, 74\u201383 (2014).","journal-title":"Pharm. Res"},{"key":"638_CR98","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.4103\/1673-5374.327348","volume":"17","author":"Y-J Zhao","year":"2022","unstructured":"Zhao, Y.-J. et al. Lithium promotes recovery after spinal cord injury. Neural Regen. Res 17, 1324\u20131333 (2022).","journal-title":"Neural Regen. Res"},{"key":"638_CR99","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1007\/s11064-018-2488-9","volume":"43","author":"B Li","year":"2018","unstructured":"Li, B. et al. Lithium inhibits GSK3\u03b2 activity via two different signaling pathways in neurons after spinal cord injury. Neurochem. Res. 43, 848\u2013856 (2018).","journal-title":"Neurochem. Res."},{"key":"638_CR100","volume":"2","author":"K Reavis","year":"2023","unstructured":"Reavis, K., Abrams, M., Dimas, G., Meier, N. & Fusick, A. J. Lithium for pain management and suicidality in spinal cord injury patients: a case report and review of the literature. Psychiatry Res. Case Rep. 2, 100131 (2023).","journal-title":"Psychiatry Res. Case Rep."},{"key":"638_CR101","doi-asserted-by":"publisher","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","volume":"20","author":"M G\u00f6ttlicher","year":"2001","unstructured":"G\u00f6ttlicher, M. et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 20, 6969\u20136978 (2001).","journal-title":"EMBO J."},{"key":"638_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2021.105182","volume":"150","author":"Y Dai","year":"2021","unstructured":"Dai, Y. et al. Classical HDACs in the regulation of neuroinflammation. Neurochem Int 150, 105182 (2021).","journal-title":"Neurochem Int"},{"key":"638_CR103","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.wneu.2023.10.135","volume":"182","author":"Q Yang","year":"2024","unstructured":"Yang, Q., Zhang, H., Jin, Z., Zhang, B. & Wang, Y. Effects of valproic acid therapy on rats with spinal cord injury: a systematic review and meta-analysis. World Neurosurg. 182, 12\u201328 (2024).","journal-title":"World Neurosurg."},{"key":"638_CR104","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.4103\/1673-5374.238603","volume":"13","author":"Y Zhang","year":"2018","unstructured":"Zhang, Y. et al. Melatonin for the treatment of spinal cord injury. Neural Regen. Res 13, 1685\u20131692 (2018).","journal-title":"Neural Regen. Res"},{"key":"638_CR105","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2023.105074","volume":"146","author":"A Shvetcov","year":"2023","unstructured":"Shvetcov, A. et al. The neuroprotective effects of estrogen and estrogenic compounds in spinal cord injury. Neurosci. Biobehav. Rev. 146, 105074 (2023).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"638_CR106","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.expneurol.2014.01.008","volume":"259","author":"S Elkabes","year":"2014","unstructured":"Elkabes, S. & Nicot, A. B. Sex steroids and neuroprotection in spinal cord injury: a review of preclinical investigations. Exp. Neurol. 259, 28\u201337 (2014).","journal-title":"Exp. Neurol."},{"key":"638_CR107","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1038\/s41393-020-0483-x","volume":"58","author":"A Stampas","year":"2020","unstructured":"Stampas, A. et al. The first 24 h: opioid administration in people with spinal cord injury and neurologic recovery. Spinal Cord. 58, 1080\u20131089 (2020).","journal-title":"Spinal Cord."},{"key":"638_CR108","doi-asserted-by":"publisher","first-page":"328","DOI":"10.3171\/jns.1977.46.3.0328","volume":"46","author":"ES Flamm","year":"1977","unstructured":"Flamm, E. S. et al. Ethanol potentiation of central nervous system trauma. J. Neurosurg. 46, 328\u2013335 (1977).","journal-title":"J. Neurosurg."},{"key":"638_CR109","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1111\/ene.12145","volume":"20","author":"JC Furlan","year":"2013","unstructured":"Furlan, J. C. & Fehlings, M. G. Blood alcohol concentration as a determinant of outcomes after traumatic spinal cord injury. Eur. J. Neurol. 20, 1101\u20131106 (2013).","journal-title":"Eur. J. Neurol."},{"key":"638_CR110","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/00007632-200301010-00009","volume":"28","author":"ME Pollard","year":"2003","unstructured":"Pollard, M. E. & Apple, D. F. Factors associated with improved neurologic outcomes in patients with incomplete tetraplegia. Spine 28, 33\u201339 (2003).","journal-title":"Spine"}],"updated-by":[{"DOI":"10.1038\/s43856-025-01345-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000}}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-024-00638-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-024-00638-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-024-00638-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T08:02:53Z","timestamp":1767168173000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-024-00638-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,24]]},"references-count":110,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["638"],"URL":"https:\/\/doi.org\/10.1038\/s43856-024-00638-0","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,24]]},"assertion":[{"value":"11 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s43856-025-01345-0","URL":"https:\/\/doi.org\/10.1038\/s43856-025-01345-0","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.W. has received\/is receiving funding from Michael Smith Foundation for Health Research in partnership with the Rick Hansen Foundation, University Hospital Basel, Wellspect, Coloplast, Stoke Mandeville Spinal Research, International Foundation for Research in Paraplegia, and Swiss Multiple Sclerosis Society. M.W. reports advisory board activity for Coloplast from 2022 to 2024.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"213"}}